TREATMENT PATTERNS AND HEALTH CARE COSTS IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)TREATMENT PATTERNS AND HEALTH CARE COSTS IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)

被引：0
|
作者：
Clancy, Z. [1 ]
Bell, E. [2 ]
Chastek, B. [3 ]
Bunner, S. [3 ]
Copher, R. [1 ]
Arekapudi, S. [4 ]
机构：
[1] Bristol Myers Squibb, Summit, NJ USA
[2] Optum, Minneapolis, MN USA
[3] Optum, Eden Prairie, MN USA
[4] Univ Calif San Francisco, Fresno, CA USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN104
引用
收藏
页码：S41 / S41
页数：1
相关论文
共 50 条
  • [21] Florid marginal zone differentiation in follicular lymphoma mimicking marginal zone lymphoma of MALT type in the lung
    Jourdan, F.
    Molina, T. J.
    Le Tourneau, A.
    Machet, M. C.
    De Muret, A.
    Renjard, L.
    Fetissof, F.
    HISTOPATHOLOGY, 2006, 49 (04) : 426 - 429
  • [22] JS']JSH Practical Guidelines for Hematological Malignancies, 2023: II. Lymphoma-2. Marginal zone lymphoma: MZL (extranodal marginal zone lymphoma: EMZL [extranodal marginal zone lymphoma of mucosa associated lymphoid tissue], nodal marginal zone lymphoma: NMZL, splenic marginal zone lymphoma: SMZL)
    Yoshida, Isao
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2025,
  • [23] Follicular lymphoma presenting like marginal zone lymphoma: A case report
    Peng, Hao-Yu
    Xiu, Ying-Jie
    Chen, Wei-Hong
    Gu, Qing-Li
    Du, Xin
    WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (17) : 5877 - 5883
  • [24] Follicular lymphoma presenting like marginal zone lymphoma:A case report
    Hao-Yu Peng
    Ying-Jie Xiu
    Wei-Hong Chen
    Qing-Li Gu
    Xin Du
    World Journal of Clinical Cases, 2022, 10 (17) : 5877 - 5883
  • [25] REVIEW OF BURDEN OF ILLNESS DATA FOR FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA
    Monga, N.
    Garside, J.
    Quigley, J. M.
    O'Donovan, P.
    Ward, K. E.
    Padhiar, A.
    Parisi, L.
    Tapprich, C.
    VALUE IN HEALTH, 2017, 20 (05) : A102 - A102
  • [26] Umbralisib Receives Accelerated Approval for Marginal Zone Lymphoma and Follicular Lymphoma
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (03) : 175 - 175
  • [27] A phase 3 study to evaluate the efficacy and safety of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL).
    Sehn, Laurie Helen
    Scholz, Christian W.
    Luminari, Stefano
    Salar, Antonio
    Wahlin, Bjorn E.
    Gopal, Ajay K.
    Bonnet, Christophe Marc
    Paneesha, Shankara
    Manzke, Oliver
    Seguy, Francis
    Li, Di
    Huebel, Kai
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] Methylation patterns in marginal zone lymphoma
    Arribas, Alberto J.
    Bertoni, Francesco
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2017, 30 (1-2) : 24 - 31
  • [29] DURABLE RESPONSES WITH IDELALISIB MONOTHERAPY IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL)
    Gyan, E.
    Martin, P.
    Armas, A.
    Gopal, A. K.
    Wagner-Johnston, N. D.
    Abella-Dominicis, E.
    Ye, W.
    Philip, B.
    Sorenson, B.
    Walewski, J.
    de Vos, S.
    HAEMATOLOGICA, 2016, 101 : 757 - 758
  • [30] Myeloid Cell Nuclear Differentiation Antigen (MNDA) in the Diagnostic Evaluation of B-Cell Lymphomas: A Novel Marker in the Differential Diagnosis of Low Grade Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL)
    Gupta, Neha
    Aldabagh, Mohammad
    Brody, Judith
    Hsu, Peihong
    Sheikh, Ayesha
    Reddy, Kalpana
    Zhang, Xinmin
    Sheikh-Fayyaz, Silvat
    LABORATORY INVESTIGATION, 2018, 98 : 519 - 519
12345